Related by context. All words. (Click for frequent words.) 84 refractory acute lymphoblastic 83 relapsed acute lymphocytic 78 refractory acute lymphocytic 73 Ph + acute lymphoblastic 72 Annamycin 69 leukemia ALL 69 refractory chronic lymphocytic 69 tumors GIST 69 precursor acute lymphoblastic 68 Amgen Neulasta R 68 metastatic renal cell 68 metastatic pancreatic 68 Relapsed Refractory 68 pediatric acute lymphoblastic 67 previously untreated follicular 67 drug Treanda 67 SPRYCEL ® 67 Amgen Neulasta ® 67 lymphoma multiple myeloma 67 refractory indolent non 66 bladder ovarian 66 castration resistant hormone refractory 66 resistant hormone refractory 66 leukemia AML 66 Philadelphia Chromosome Positive 66 refractory anaplastic astrocytoma 66 Bayer Nexavar 66 follicular Non Hodgkin 66 imatinib Gleevec ® 66 mitoxantrone plus 66 cell acute lymphoblastic 66 Fludarabine 66 essential thrombocythemia ET 66 lintuzumab SGN 66 LymphoStat B belimumab 65 Chronic lymphocytic leukemia CLL 65 metastatic renal 65 refractory chronic myeloid 65 Non Hodgkin 65 AML acute myeloid 65 metastatic malignant 65 Temodar ® 65 Acute myelogenous leukemia 65 ZACTIMA TM ZD# 65 hematological cancers notably 65 MabThera Rituxan 65 Peginterferon alfa 2b 65 relapsed MM 65 chemosensitizer 65 Kit CD# positive 65 hormone refractory metastatic prostate 65 basal cell carcinoma squamous 65 indolent follicular non 65 CYT# potent vascular disrupting 65 ® lenalidomide 65 Brentuximab Vedotin SGN 65 myelodysplastic myeloproliferative diseases 64 Troxatyl 64 lung esophageal 64 progressive metastatic prostate 64 Roche Actemra 64 recurrent metastatic 64 leukemia lymphoma multiple myeloma 64 refractory cutaneous T 64 stage IIIb IV 64 pancreatic prostate 64 Ribavirin causes 64 rituximab refractory follicular 64 AVASTIN 64 systemic anaplastic large 64 non splenectomized 64 Chronic Myelogenous Leukemia CML 64 Chronic lymphocytic leukemia 64 deCODE ProstateCancer TM 64 Adjuvant Treatment 64 Prednisone Against Refractory 64 Relapsed Refractory Aggressive 64 gastrointestinal stromal 64 leukemia multiple myeloma 64 LHRH receptor positive 64 dasatinib Sprycel ® 64 metastatic colorectal 64 cyclophosphamide doxorubicin vincristine 64 Evoltra ® 64 thalidomide Thalomid 64 Cutaneous T 64 relapsed Acute Myeloid 64 recurrent NSCLC 64 de novo kidney transplant 63 metastatic androgen independent 63 CLL SLL 63 Acute Myeloid Leukaemia AML 63 Vidaza ® 63 Combination REOLYSIN R 63 lymphocytic leukemia 63 commercialize deforolimus 63 subependymal giant cell 63 Leukemias 63 recurrent glioblastoma multiforme 63 demonstrated antitumor activity 63 relapsed refractory AML 63 Shows Efficacy 63 Achieves Primary Endpoint 63 macroglobulinemia 63 breast pancreatic 63 alemtuzumab Campath 63 chronically immunosuppressed solid 63 dasatinib Sprycel 63 ZACTIMA 63 Severe Sepsis 63 brain metastases originating 63 evaluating picoplatin 63 Acute Myelogenous Leukemia AML 63 Refractory Hodgkin Lymphoma 63 refractory acute promyelocytic 63 Glioblastoma Multiforme 63 cause mesothelioma asbestosis 63 whose tumors overexpress 63 Patients Receiving 63 Bosutinib 63 carcinoma HCC 63 BRAF mutant 63 Newly Diagnosed Chronic Myeloid 63 evaluating tivozanib 63 untreated metastatic pancreatic 63 lymphoma leukemia 63 Improves Outcomes 63 hypereosinophilic syndrome 63 acute myeloid 63 5 FU leucovorin 63 oropharyngeal candidiasis OPC 63 Flu Cy 63 muscular dystrophy cystic fibrosis 63 Anthracycline 63 Amrubicin 63 Hormone Refractory Prostate Cancer 63 hormone receptor negative 63 Newly Diagnosed Multiple Myeloma 63 non resectable 62 CIMZIA r certolizumab pegol 62 damage cirrhosis liver 62 ErbB2 positive 62 cirrhosis liver failure 62 Idiopathic Pulmonary Fibrosis 62 Medullary thyroid cancer 62 smoldering myeloma 62 advanced hepatocellular carcinoma 62 completely resected 62 anaplastic astrocytoma AA 62 cell carcinoma RCC 62 metastatic bladder 62 treating chronic myeloid 62 Myelodysplastic Syndrome MDS 62 Omacetaxine 62 Menopausal hormone therapy 62 lumiliximab 62 Bayer HealthCare Onyx Pharmaceuticals 62 gefitinib Iressa 62 smoldering multiple myeloma 62 Campath alemtuzumab 62 R sorafenib tablets 62 colorectal lung 62 relapsed acute myelogenous 62 radiation chemoradiation 62 Zarnestra 62 refractory Hodgkin 62 Follicular Lymphoma 62 Tesmilifene 62 leukemia APL 62 Folfox 62 assessing T DM1 62 Gleevec Glivec 62 rituximab refractory 62 refractory NSCLC 62 ovarian breast 62 gastrointestinal stromal tumors GISTs 62 taxane chemotherapy administered 62 Waldenstrom macroglobulinemia 62 metastatic hormone refractory 62 Advanced Melanoma 62 chronic myeloid 62 metastatic GIST 62 temozolomide TMZ 62 kidney urologic 62 R lenalidomide 62 Nexavar sorafenib 62 NMIBC 62 systemic juvenile idiopathic 62 refractory metastatic 62 hematological diseases 62 Roche Herceptin 62 3 registrational trial 62 non hodgkin lymphoma 62 Vidaza R 62 lenalidomide Revlimid R 62 Stage IIB 62 Vitrasert R 62 relapsed leukemia 62 Lymphocytic 62 refractory metastatic colorectal cancer 62 refractory acute myeloid 62 pancreatic colon 62 diagnosed Ph + 62 metastatic carcinoid 61 decompensated liver disease 61 chronic eosinophilic leukemia 61 ara C 61 HER2 positive metastatic breast 61 Myelodysplastic syndromes 61 Investigational Treatment 61 advanced HER2 positive 61 pancreatic colorectal 61 polycythemia vera essential thrombocythemia 61 Camptosar ® 61 Leukemia AML 61 Heterozygous Familial Hypercholesterolemia 61 gastrin analogue TT 61 leukemia CLL 61 Predict Response 61 capecitabine Xeloda 61 Phase 2b Clinical Trial 61 Initiate Clinical Trial 61 Improves Survival 61 ovarian prostate 61 acute myelogenous 61 adalimumab Humira 61 Acute myeloid leukemia 61 Tykerb lapatinib 61 HBeAg negative 61 Patients Treated With 61 triggers apoptosis programmed 61 cytarabine daunorubicin 61 squamous non 61 cyclophosphamide FC 61 achieved CCyR 61 Relapsing Remitting Multiple Sclerosis 61 lymphoproliferative disorders 61 approved incretin mimetic 61 Diffuse Large B 61 exocrine pancreatic insufficiency EPI 61 galiximab 61 myelogenous leukemia 61 myocardial infarction ventricular fibrillation 61 elderly myelodysplastic syndromes 61 acute leukemias 61 multiple myeloma MM 61 non myeloid malignancies 61 Velcade bortezomib 61 novel VDA molecule 61 HER2 Positive Breast Cancer 61 gastrointestinal stromal tumor GIST 61 metastatic castration resistant 61 lymphoid malignancies 61 Myelofibrosis 61 develop HBV reactivation 61 TTR amyloidosis 61 Stage IIIb 61 Hodgkin lymphoma HL 61 humanized interleukin 6 61 alfa 2a 61 cell lymphoma CTCL 61 Naive Patients 61 L Annamycin 61 relapsed mantle 61 intrahepatic bile duct 61 refractory colorectal cancer 61 tuberous sclerosis TS 61 advanced medullary thyroid 61 Rituxan rituximab 61 unresectable tumors 61 Acute Exacerbations 61 chronic lymphocytic 61 Antitumor Activity 61 haematologic malignancies 61 NECK CANCER SUPPORT GROUP 61 acute lymphoblastic 61 antiretroviral naïve 61 evaluating T DM1 61 stage IIIB IV 61 drug figitumumab 61 Farrah Fawcett dies 61 follicular lymphoma FL 61 Shows Promise Against 61 PROCRIT ® 61 Tramiprosate ALZHEMED TM 61 non metastatic osteosarcoma 61 refractory AML 61 acute GvHD 61 Glioblastoma multiforme GBM 61 FOLFIRI alone 61 Epratuzumab 61 cisplatin gemcitabine 61 gemcitabine Gemzar ® 61 TNFerade ™ 61 Drug Shows Promise 61 oblimersen 61 Lupus Nephritis 61 sarcoma melanoma 61 Pfizer Camptosar 61 chemotherapy fludarabine 61 metastatic gastric 61 Acute lymphoblastic leukemia 61 Demonstrates Significant 61 pegylated liposomal doxorubicin 61 bortezomib Velcade R 61 5 fluorouracil leucovorin 61 FOLFOX6 chemotherapy regimen 61 BARACLUDE ® 60 Juvenile Idiopathic Arthritis 60 hepatocellular carcinoma liver 60 Completes Patient Enrollment 60 receiving chemoradiation therapy 60 rheumatoid arthritis psoriatic arthritis 60 Merck KGaA Erbitux 60 deCODE AF TM 60 Temsirolimus 60 Mantle Cell Lymphoma 60 chronic immune thrombocytopenic 60 paclitaxel Taxol ® 60 idiopathic thrombocytopenic purpura ITP 60 biliary tract cancer 60 Taxotere docetaxel 60 unresectable recurrent 60 underwent surgical resection 60 Plicera TM 60 Stage IIIB IV 60 Atypical Hemolytic Uremic Syndrome 60 TO AVOID PREGNANCY WHILE 60 Cell Lymphoma 60 Cimzia TM 60 including eniluracil ADH 60 Anaplastic 60 deep venous thromboses 60 FluCAM arm 60 leukemia lymphomas 60 docetaxel Injection Concentrate 60 Renal Cell Carcinoma RCC 60 PLX STROKE targeting 60 initiated Phase Ib 60 Sanofi Aventis Taxotere 60 PI3K/Akt pathway inhibitor 60 Gemzar gemcitabine 60 Cloretazine 60 erlotinib Tarceva ® 60 TTF Therapy 60 rALLy 60 etanercept Enbrel 60 cutaneous T 60 non resectable metastatic 60 castrate resistant 60 thetreatment 60 naïve HCV 60 T1c 60 Acute Myelogenous Leukemia 60 chronic thromboembolic pulmonary 60 CHOP cyclophosphamide doxorubicin vincristine 60 anti PlGF 60 Genentech Rituxan 60 LSE ASM 60 efaproxiral 60 advanced unresectable 60 pediatric pontine glioma 60 Hairy Cell 60 HBeAg + 60 non CF bronchiectasis 60 Postmenopausal hormone therapy 60 atypical rhabdoid tumor 60 severe oral mucositis 60 juvenile myelomonocytic leukemia 60 Antisoma AS# 60 HER2 amplified 60 INSPIRE Trial Phase III 60 Vidaza azacitidine 60 Novantrone 60 Novel Oral 60 metastatic CRC 60 autoantibody positive 60 MKC# MT 60 TNF Blockers 60 Ixempra 60 anthracycline taxane 60 biliary cancer 60 irinotecan doxorubicin oxaliplatin paclitaxel 60 Imatinib mesylate 60 pertuzumab 60 TNFerade TM 60 Treatment Naïve 60 Acute Myeloid Leukemia 60 Chronic Myeloid Leukemia 60 Allovectin 7 60 aMCI precursor 60 endometrial breast 60 small lymphocytic lymphoma 60 nonmetastatic 60 receptor tyrosine kinase inhibitor 60 EGFR mutation positive 60 FOLFOX chemotherapy 60 pancreatic neuroendocrine tumors 60 Chronic myeloid leukemia 60 ThermoDox R 60 moderate immunologic 60 Initiates Enrollment 60 rhabdoid 60 oxypurinol 60 hepatocellular cancer 60 Aflibercept 60 sapacitabine CYC# 60 VEGFR2 inhibitor 60 ORAL HEAD AND 60 Previously Untreated 60 corticosteroid dexamethasone 60 Chronic Lymphocytic Leukemia CLL 60 metastatic colorectal carcinoma 60 oncolytic virus therapies 60 FOLFOX6 60 metastatic castrate resistant 60 progressive neurodegenerative 60 humanized therapeutic 60 UCB Cimzia 60 RhuDex TM 60 FUSILEV enhances 60 chronic HBV 60 advanced carcinoid 60 idiopathic thrombocytopenic purpura 60 asthma rheumatoid arthritis 60 Cholangiocarcinoma 60 CHOP chemotherapy 60 anthracycline containing 60 CTAP# Capsules 60 Slow Progression 60 included exfoliative dermatitis 60 Glufosfamide 60 papillary renal cell carcinoma 60 Soft Tissue Sarcoma 60 Treatment Shows Promise 60 Acute Myeloid Leukemia AML 60 Xelox 60 TNF Tumor Necrosis Factor 60 EGFR expressing mCRC 60 accumulate preferentially 60 Shows Promising 60 metastatic malignant melanoma 60 paclitaxel Taxol R 60 Advanced Renal Cell 60 reduce serum phosphate 60 oral clodronate 60 leukaemias 60 SJIA 60 Recurrent Glioblastoma 60 Enzastaurin 60 Dasatinib 60 haematologic 60 interferon beta 1a infertility 59 ovarian endometrial 59 Oral Fingolimod 59 myeloid metaplasia 59 SILENOR TM doxepin HCl 59 esthesioneuroblastoma rare form 59 Personalized Immunotherapy 59 hepatorenal syndrome 59 allogeneic hematopoietic stem cell 59 bone marrow reticulin deposition 59 Hsp# Inhibitor 59 PRN FDA Approves 59 Node Positive 59 relapsed follicular lymphoma 59 lymphomas leukemias 59 Basal Cell 59 oral squamous cell 59 Squamous 59 Sprycel dasatinib 59 sunitinib Sutent 59 cetuximab Erbitux 59 refractory gastrointestinal stromal 59 Nat Rev 59 HRPC ovarian cancer 59 malignant ascites 59 antibody MAb 59 acute myelogenous leukemia AML 59 Elotuzumab 59 bone marrow malignancy 59 Papillary 59 gastrointestinal mucositis 59 Metastatic Melanoma 59 PTK# 59 metastatic kidney 59 Fludara ® 59 Previously Treated 59 Castration Resistant Prostate Cancer 59 Herceptin trastuzumab 59 Cell Non Hodgkin 59 receiving immunosuppressive therapy 59 sorafenib tablets 59 chronic rheumatic 59 Gene Mutation Linked 59 indolent NHL 59 recurrent epithelial ovarian 59 plus dexamethasone 59 hyperphenylalaninemia HPA due 59 NYSE Amex YMI 59 Zolinza 59 Avastin Tarceva 59 ® bortezomib 59 melanoma ovarian 59 recurrent malignant glioma 59 PF # [002] 59 Insegia 59 motesanib 59 B Cell Lymphoma 59 Ivanhoe Newswire Patients 59 advanced metastatic renal 59 PANVAC VF 59 GlaxoSmithKline Tykerb 59 Gastrointestinal Stromal Tumors 59 Quinamed 59 BRAF V# mutation 59 carcinoma mCRC 59 Myelodysplastic Syndrome 59 atypical Hemolytic Uremic Syndrome 59 Erlotinib 59 Gleevec resistant 59 unresectable Stage III 59 moderate renal impairment 59 CD# antibody [002] 59 LymphoStat B TM 59 substantially excreted 59 cetuximab Erbitux ® 59 TRACON Pharmaceuticals 59 orally administered inhibitor 59 cyclophosphamide chemotherapy 59 Mg Usa 59 tramiprosate Alzhemed TM 59 Femara letrozole 59 gemcitabine chemotherapy 59 vaccine GMK 59 relapsed multiple myeloma 59 untreated metastatic colorectal 59 leukemias lymphomas 59 systemic ALCL 59 lenalidomide Revlimid 59 Is Well Tolerated 59 pancreatic insufficiency 59 HIV coinfected 59 CIMZIA TM certolizumab pegol 59 prednisone CHOP 59 unresectable locally advanced 59 AN# topical anti 59 OSI Tarceva 59 GVAX ® 59 Meets Primary Endpoint 59 Chronic Lymphocytic Leukemia 59 systemic invasive fungal 59 Bevacizumab Avastin 59 BRIM2 59 MAGE A3 ASCI 59 Carcinoid tumors 59 Panzem R 59 brand ciclesonide HFA 59 refractory Ph + 59 Boosts Survival 59 treat musculoskeletal metabolic 59 ritonavir boosted 59 mapatumumab 59 unresectable stage 59 mRCC 59 severe malignant osteopetrosis 59 undergoing hematopoietic stem 59 CVP cyclophosphamide vincristine 59 GW# [003] 59 opioid naive 59 arthritis PsA 59 panitumumab Vectibix 59 finasteride Proscar 59 VALSTAR TM 59 atypical hemolytic uremic syndrome 59 uterine fibroid induced 59 Alessandro Riva 59 relapsing remitting MS RRMS 59 2 methoxyestradiol 59 Pruvel TM 59 Complicated Skin 59 R Saizen R 59 Newly Diagnosed Patients 59 Hedgehog Pathway Inhibitor 59 stage IIIb 59 trastuzumab Herceptin R 59 Raptiva efalizumab 59 docetaxel cisplatin 59 oral ridaforolimus 59 Rituximab 59 Azacitidine 59 Dementia Related Psychosis 59 irinotecan containing 59 glioblastoma multiforme GBM 59 gemcitabine carboplatin 59 alpha folate receptor 59 include ColorectAlert TM 59 LungAlert TM 59 commercialize deforolimus ARIAD 59 Estrogen receptor positive 59 anaplastic astrocytoma 59 Romiplostim 59 diagnosed glioblastoma multiforme 59 Non Hodgkins lymphoma 59 Namenda Memantine HCl 59 estramustine 59 MCyR 59 acyclovir Lauriad R 59 VNP#M 59 Systemic Juvenile Idiopathic 59 CYT# vascular disrupting 59 Novartis Afinitor 59 Phase #/#a trial 59 unresectable metastatic 59 prostate pancreatic 59 lung pancreatic 59 forodesine 59 Prolongs Survival 59 lymphoblastic leukemia 59 ASONEP TM 59 Submits Biologics License Application 58 RANK Ligand inhibitor 58 ovarian esophageal 58 investigational monoclonal antibody 58 pediatric Crohn disease 58 minimally symptomatic 58 sunitinib malate 58 SinuNase TM 58 Adjuvant chemotherapy 58 Relapsed Multiple Myeloma 58 diagnosed chronic myeloid 58 Lilly Alimta 58 sirtuin inhibitor program 58 receiving XGEVA 58 Arimidex anastrozole 58 Biogen Genentech 58 SNT-MC#/idebenone 58 candidates Azedra TM 58 metastatic carcinoma 58 hoFH 58 diseases fat malabsorption 58 selective angiogenic kinase inhibitor 58 lymphoma Hodgkin lymphoma 58 Introgen ADVEXIN 58 Malignant Melanoma 58 myeloproliferative neoplasms MPNs 58 BCG refractory carcinoma 58 sorafenib Nexavar ® 58 phase IIb trial 58 lupus erythematosus 58 Myelodysplasia 58 Paraplatin ® 58 Archexin 58 Vicriviroc 58 cancer mCRC 58 chronic lymphocytic leukemia CLL 58 systemic autoimmune 58 ixabepilone 58 chronic idiopathic thrombocytopenic purpura 58 Arzerra ofatumumab 58 atherosclerosis rheumatoid arthritis 58 pancreatic bladder 58 Improved Survival 58 gemcitabine cisplatin 58 oral deforolimus 58 progesterone receptor negative 58 castrate resistant prostate cancer 58 CTAP# 58 Azmacort R 58 Multiple Sclerosis Rheumatoid Arthritis 58 registrational trial 58 SinuNase ™ 58 PNP inhibitor 58 Regeneron Pharma 58 colon ovarian 58 sunitinib Sutent ® 58 Degarelix 58 Trastuzumab 58 alvespimycin 58 NICE Recommends 58 Crizotinib 58 Crofelemer budesonide foam 58 intra arterial chemotherapy 58 non squamous 58 IRX 2 58 ORENCIA ® 58 IMiDs ® 58 R abatacept 58 immune thrombocytopenic purpura 58 Appears Safe 58 Gleevec imatinib mesylate 58 OVARIAN 58 Targretin capsules 58 plus gemcitabine 58 sorafenib Nexavar 58 hypertrichosis occurred 58 MGd 58 8mg/kg 58 Idiopathic pulmonary fibrosis 58 KRAS wild 58 ER CHOP 58 Cyclacel Pharmaceuticals 58 Phase 2a Trial 58 ® bevacizumab 58 Preclinical Models 58 MCSP respectively 58 Begins Dosing 58 Cotara ® 58 ZOLINZA 58 compound INCB# 58 Oral Cladribine 58 opioid induced constipation OIC 58 metastatic HER2 negative 58 neutropenia dehydration dyspnea 58 humanised monoclonal antibody 58 Recurrent Chest Wall 58 metastatic ocular 58 Medivation Inc 58 Xeloda ® 58 Relapsed Refractory Multiple Myeloma 58 Phase Ib IIa 58 adjuvant cisplatin 58 hematologic disorders 58 secondary hyperparathyroidism 58 Temodar temozolomide 58 Zorbtive TM 58 DCVax ® Brain 58 nonsmall cell lung cancer 58 TNF blocker therapy 58 omacetaxine mepesuccinate 58 Phase #b/#a clinical 58 relapsed ALL 58 HeFH 58 Provectus Pharmaceuticals specializes 58 ALN VSP Phase 58 albiglutide currently 58 developer Antisoma plc 58 Receives Orphan Drug Designation 58 Demonstrates Positive 58 metaglidasen 58 docetaxel Taxotere ® 58 pancreatic adenocarcinoma 58 VANTAS ® 58 Pegloticase 58 Hepatocellular Carcinoma HCC 58 Tasigna nilotinib 58 Kinoid 58 FEMALES SHOULD BE ADVISED 58 Neulasta R 58 DEB# 58 squamous cell carcinoma SCC 58 Pemetrexed 58 Pegylated interferon 58 Arranon 58 histone deacetylase HDAC inhibitor 58 oligodendrogliomas 58 ovarian colon 58 Euronext Paris BIO 58 HCV Protease Inhibitor 58 TELINTRA R 58 infliximab monotherapy 58 gastrointestinal stromal tumors GIST 58 ELACYT 58 plus prednisone prednisolone 58 plaque buildup restricts 58 ovarian lung 58 monoclonal antibody conjugated 58 myeloproliferative neoplasms 58 neuropathic pain spasticity 58 malignant pleural mesothelioma 58 invasive lobular 58 cyclophosphamide methotrexate 58 non Hodgkins Lymphoma 58 GetGoal Phase III 58 oral picoplatin 58 resectable pancreatic cancer 58 vaccine Stimuvax 58 anthracyclines taxanes 58 Myeloma Patients 58 blastic 58 Tyrosine Kinase Inhibitors 58 CR nPR 58 patientswith 58 induce remission 58 Renal Cell Carcinoma 58 ATRA IV 58 malignant lymphoma 58 Sezary syndrome 58 parathyroid carcinoma 58 grade cervical dysplasia 58 neutropenic sepsis 58 small molecule tyrosine 58 induced anemia 58 radiotherapy RT 58 sargramostim 58 Vitaxin 58 cervical ovarian 58 bacillus Calmette Guerin 58 Dacogen injection 58 tumor xenograft models 58 Intravitreal 58 immune thrombocytopenic purpura ITP 58 Genasense ® 58 systemic mastocytosis 58 adverse cytogenetics 58 bendamustine 58 recurrent glioblastoma 58 Platinol ® 58 Safinamide 58 treating sarcoma testicular 58 Multiple Myeloma MM 58 FDA Approves Drug 58 Basal cell 58 EGFR tyrosine kinase inhibitor 58 trial evaluating PRX# 58 biochemical relapse 58 HIV treatments Reyataz 58 malignant pleural mesothelioma MPM 58 HGS ETR1 mapatumumab 58 ASONEP ™ 58 keloid scarring 58 hematopoietic cancers 58 radioimmunotherapeutic agent 58 patients coinfected 58 asthma emphysema bronchitis 58 Zytiga 58 Treatment Naive Patients 58 Nilotinib 58 purpura ITP 58 recurrent glioblastoma multiforme GBM 58 allogeneic bone marrow 58 eosinophilic asthma 58 neoadjuvant treatment 58 neuroendocrine cancers 58 generation purine nucleoside 58 leukemia aplastic anemia 58 locoregional recurrence 58 ® darbepoetin alfa 58 PROSTVAC VF 58 midstage clinical 58 bortezomib refractory 58 novel emulsion formulation 58 mycosis fungoides 58 DepoCyt 58 docetaxel Taxotere R 57 MALT lymphoma 57 Pegylated Interferon 57 Fluorouracil 57 combining voreloxin 57 CYP#A# substrate 57 developing Bicifadine serotonin 57 dacarbazine DTIC 57 histologic subtype 57 peripheral sensory neuropathy 57 Hepatocellular 57 mycophenolic acid 57 Neoadjuvant 57 opsoclonus myoclonus syndrome 57 Cytarabine 57 NSABP C 57 acute lymphoid leukemia 57 haemolytic uraemic syndrome 57 Tarceva erlotinib 57 imatinib Gleevec 57 generation PNP inhibitor 57 liver decompensation 57 endocrine refractory 57 Initiates Clinical Trial 57 virus HCV protease inhibitor 57 Inhaled nitric oxide 57 Relapsed 57 Muraglitazar 57 XL# anticancer compounds 57 ovarian pancreatic 57 de novo AML 57 elotuzumab 57 dyslipidemia hypertension diabetes 57 benign neoplasms 57 alpha1 antitrypsin deficiency 57 prednisone prednisolone plus 57 commercializes oncology 57 brivanib 57 cisplatin resistant 57 acetonide FA 57 mouse xenograft models 57 CYP#A# CYP#D# 57 colorectal liver 57 Granted Orphan Drug 57 Modrenal R 57 Initiates Phase II 57 pain palliation 57 Tarceva TM 57 Mg Uk 57 doublet chemotherapy 57 tyrosine kinase inhibitor TKI 57 IMiDs ® compound 57 relapsed refractory 57 Jevtana 57 Pharmacokinetics PK 57 psoriatic arthritis PsA 57 Gene Linked 57 delivers fluocinolone acetonide FA 57 chronic granulomatous disease 57 CG# oncolytic virus 57 EGFR HER2 57 Alzhemed TM 57 allogeneic HSCT 57 Copegus ribavirin 57 BRAF inhibitor 57 fallopian tube carcinoma 57 gastric pancreatic 57 Racivir 57 RoACTEMRA 57 Paraplatin ® carboplatin 57 T Cell Lymphoma 57 lapatinib Tykerb 57 Systemic Sclerosis 57 familial amyloidotic polyneuropathy FAP 57 skeletal metastases 57 Interferon beta 57 low dose cytarabine 57 PKC# 57 thyroid carcinoma 57 relapsed refractory multiple myeloma 57 AAG geldanamycin analog 57 Clolar ® 57 nilotinib Tasigna ® 57 enterocolitis 57 ORENCIA R 57 nucleotide analog 57 gemcitabine Gemzar 57 Taxotere chemotherapy 57 gastrointestinal stromal tumors 57 recurrent colorectal cancer 57 Pivotal Study 57 transplantation HCT 57 include Healive TM 57 IG HCR ;) CO 57 Acute myeloid leukemia AML 57 Pertuzumab 57 patients receiving myelosuppressive 57 steroid refractory GvHD 57 non porcine pancreatic 57 Graft Versus Host 57 HER2 positive metastatic 57 metastatic dermatofibrosarcoma protuberans DFSP 57 recurrent squamous cell carcinoma 57 Pegasys peginterferon alfa 2a 57 Alemtuzumab 57 toenail onychomycosis 57 HP Acthar Gel repository 57 achieved ACR# 57 Leukemia lymphoma 57 Telintra 57 Platinol ® cisplatin 57 oxaliplatin Eloxatin 57 taxane therapy 57 KRAS mutated 57 deletion 5q 57 chronic myeloid leukemia CML 57 Phase IIb Trial 57 BR.# 57 nodal metastasis 57 Certolizumab pegol 57 dirucotide MBP# 57 pancreatic lung 57 Pathway Inhibitor 57 myelodysplastic syndrome MDS 57 Chemotherapy Improves 57 severe hepatic dysfunction 57 lintuzumab 57 Ceflatonin R 57 CIMZIA TM 57 refractory CLL 57 hormonally sensitive 57 Raptiva ® 57 expressing metastatic colorectal 57 colorectal cancer liver metastases 57 relapsed refractory aggressive 57 enzastaurin 57 adriamycin 57 novel immunotherapies 57 EGFR TKI 57 Pharmion Vidaza 57 Glioblastoma Multiforme GBM 57 Zybrestat 57 DVT prophylaxis cholesterol 57 Plaquenil 57 Treatment Experienced 57 Sapacitabine 57 hereditary pancreatitis 57 TroVax ® 57 HER2 + 57 Idiopathic Thrombocytopenic Purpura 57 Follicular lymphoma 57 cetuximab Erbitux R 57 phase IIb study 57 refractory myeloma 57 preeclampsia gestational diabetes